SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-029833
Filing Date
2022-11-14
Accepted
2022-11-14 16:12:20
Documents
48
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nltx-20220930.htm   iXBRL 10-Q 1273730
2 EX-31.1 exhibit3112022q3.htm EX-31.1 9551
3 EX-32.1 exhibit3212022q3.htm EX-32.1 6116
  Complete submission text file 0001628280-22-029833.txt   4514960

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20220930.xsd EX-101.SCH 21979
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nltx-20220930_cal.xml EX-101.CAL 40941
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nltx-20220930_def.xml EX-101.DEF 114644
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20220930_lab.xml EX-101.LAB 385428
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20220930_pre.xml EX-101.PRE 235764
42 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20220930_htm.xml XML 616488
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36327 | Film No.: 221385386
SIC: 2834 Pharmaceutical Preparations